1. The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China; 2. Institute of Pathogen Biology, CAMS & PUMC,Beijing 100176, China;
Abstract:This study aimed to establish a method for preparing recombinant Mycobacterium tuberculosis ArgRS and to verify the biological activity of the recombinant protein. The ArgRS gene of Mycobacterium tuberculosis was inserted into the pQE60 plasmid. Recombinant protein expression was induced by IPTG, and the protein was purified by gel filtration chromatography. Circular dichroism was used to evaluate the folding of the recombinant protein, and thermal shift assays were used to verify its biological activity. Then the recombinant ArgRS obtained via the pQE60 vector was purified by gel filtration chromatography, and its molecular weight was verified to be consistent with that of the natural protein. Thermal shift assays indicated the biological activity of the recombinant protein. The recombinant ArgRS had biological activity comparable to that of the natural protein and was crystallized.
[1] Dooley KE, Phillips PP, Nahid P, et al.Challenges in the clinical assessment of novel tuberculosis drugs[J]. Adv Drug Deliv Rev,2016,102:116-122. DOI: 10.1016/j.addr.2016.01.014 [2] Zhang P, Ma S.Recent development of leucyl-tRNA synthetase inhibitors as antimicrobial agents[J]. Medchemcomm, 2019,10(8):1329-1341. DOI: 10.1039/c9md00139e [3] Ho JM, Bakkalbasi E, Söll D, et al.Drugging tRNA aminoacylation[J]. RNA Biol,2018,15(4/5):667-677. DOI: 10.1080/15476286.2018.1429879 [4] Francklyn CS, Mullen P.Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics[J]. J Biol Chem,2019,294(14):5365-5385. DOI: 10.1074/jbc.REV118.002956 [5] Ziegelbauer K, Babczinski P, Schonfeld W.Molecular mode of action of the antifungal beta-amino acid BAY 10-8888[J]. Antimicrob Agents Chemother, 1998,42(9):2197-2205. DOI: 10.1128/AAC.42.9.2197 [6] Petraitis V, Petraitiene R, Kelaher AM, et al.Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans[J]. Antimicrob Agents Chemother, 2004,48(10):3959-3967. DOI: 10.1128/AAC.48.10.3959-3967.2004 [7] Petraitiene R, Petraitis V, Kelaher AM, et al.Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits[J]. Antimicrob Agents Chemother, 2005,49(5): 2084-2092. DOI: 10.1128/AAC.49.5.2084-2092.2005 [8] Werner RG.Uptake of indolmycin in gram-positive bacteria[J]. Antimicrob Agents Chemother, 1980, 18(6): 858-862. DOI: 10.1128/aac.18.6.858 [9] Werner RG, Thorpe LF, Reuter W, et al.Indolmycin inhibits prokaryotic tryptophanyl-tRNA ligase[J]. Eur J Biochem, 1976,68(1): 1-3. DOI: 10.1111/j.1432-1033.1976.tb10758.x [10] Yu XY, Hill JM, Yu G, et al.Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNA synthetases[J]. Bioorg Med Chem Lett, 1999,9(3): 375-380. DOI: 10.1016/s0960-894x(98)00738-0 [11] Jarvest RL, Berge JM, Brown P, et al.Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity[J]. Bioorg Med Chem Lett, 2003,13(7): 1265-1268. DOI: 10.1016/s0960-894x(03)00093-3 [12] Jarvest RL, Berge JM, Brown MJ, et al.Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity[J]. Bioorg Med Chem Lett, 2003,13(4): 665-668. DOI: 10.1016/s0960-894x(02)01027-2 [13] Jarvest RL. Armstrong SA, Berge JM, et al.Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues[J]. Bioorg Med Chem Lett, 2004,14(15): 3937-3941. DOI: 10.1016/j.bmcl.2004.05.070 [14] Kim JG, Park BK, Kim SU, et al.Bases of biocontrol: sequence predicts synthesis and mode of action of agrocin 84, the Trojan horse antibiotic that controls crown gall[J]. Proc Natl Acad Sci U S A, 2006,103(23): 8846-8851. DOI: 10.1073/pnas.0602965103 [15] Palencia A, Li X, Bu W, et al.Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase[J]. Antimicrob Agents Chemother, 2016,60(10): 6271-6280. DOI: 10.1128/AAC.01339-16 [16] Hurdle JG, O’Neill AJ, Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents[J]. Antimicrob Agents Chemother,2005,49(12):4821-4833. DOI: 10.1128/AAC.49.12.4821-4833.2005 [17] Pohlmann J, Brötz-Oesterhelt H.New aminoacyl-tRNA synthetase inhibitors as antibacterial agents[J]. Curr Drug Targets Infect Disord, 2004,4(4):261-272. DOI: 10.2174/1568005043340515 [18] Tao J, Schimmel P.Inhibitors of aminoacyl-tRNA synthetases as novel anti-infectives[J]. Expert Opin Investig Drugs,2000,9(8):1767-1775. DOI: 10.1517/13543784.9.8.1767 [19] Kalidas S, Cestari I, Monnerat S, et al.Genetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma brucei[J]. Eukaryot Cell,2014,13(4):504-516. DOI: 10.1128/EC.00017-14